Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김윤환 | * |
dc.date.accessioned | 2019-02-15T16:30:08Z | - |
dc.date.available | 2019-02-15T16:30:08Z | - |
dc.date.issued | 2019 | * |
dc.identifier.issn | 0090-8258 | * |
dc.identifier.issn | 1095-6859 | * |
dc.identifier.other | OAK-24321 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/248385 | - |
dc.description.abstract | Purpose. To evaluate the effectiveness of bevacizumab with single-agent chemotherapy for platinum resistant ovarian cancer in a real-world setting. Patients and methods. We enrolled recurrent platinum-resistant ovarian cancer patients from 27 institutions. All had received bevacizumab with single-agent chemotherapy (weekly paclitaxel, pegylated liposomal doxorubicin (PLD), topotecan) between 2015 and 2017 for second- or third-line chemotherapy in routine clinical practice. The primary endpoint was progression-free survival (PFS) and safety. Secondary endpoints included the objective response rate (ORR), PFS2, overall survival, duration of chemotherapy, and reasons for discontinuing chemotherapy. Results. Of 391 patients, 259 (66.2%) received bevacizumab with PLD, 94 (24.0%) with topotecan, and 38 (9.7%) with weekly paclitaxel. The median PFS was 6.1 months with all forms of bevacizumab-containing therapy. Although the cohort with weekly paclitaxel had a better PFS than the PLD cohort (P = 0.028), this finding was not found in patients with a previous platinum-free interval of less than three months. The median duration of therapy was five cycles (range, one to 20 cycles), and 29 patients (7.4%) discontinued treatment because of adverse events from bevacizumab-containing regimens. The PLD cohort had fewer grade >= 3 adverse events than the other regimens (PLD, 35.8%; weekly paclitaxel, 52.6%; topotecan, 51.1%; P = 0.012), especially events of hematologic toxicities. Conclusion. In Korean ovarian cancer patients, the safety and effectiveness of chemotherapy with bevacizumab in a real-world setting was consistent with the results from a randomized controlled study. The effectiveness and toxicity profiles varied among the chemotherapy regimens, and this finding should be considered in practice. (C) 2018 Elsevier Inc. All rights reserved. | * |
dc.language | English | * |
dc.publisher | ACADEMIC PRESS INC ELSEVIER SCIENCE | * |
dc.subject | Ovarian cancer | * |
dc.subject | Platinum-resistant | * |
dc.subject | Bevacizumab | * |
dc.subject | Chemotherapy | * |
dc.subject | Real world | * |
dc.title | Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041) | * |
dc.type | Article | * |
dc.type | Proceedings Paper | * |
dc.relation.issue | 1 | * |
dc.relation.volume | 152 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 61 | * |
dc.relation.lastpage | 67 | * |
dc.relation.journaltitle | GYNECOLOGIC ONCOLOGY | * |
dc.identifier.doi | 10.1016/j.ygyno.2018.10.031 | * |
dc.identifier.wosid | WOS:000456637000011 | * |
dc.author.google | Lee, Jung-Yun | * |
dc.author.google | Park, Jeong-Yeol | * |
dc.author.google | Park, Sang Yoon | * |
dc.author.google | Lee, Jeong-Won | * |
dc.author.google | Kim, Jae Weon | * |
dc.author.google | Kim, Yong Beom | * |
dc.author.google | Jeong, Dae Hoon | * |
dc.author.google | Lee, Kwang-Beom | * |
dc.author.google | Kim, Tae-Hun | * |
dc.author.google | Lee, In Ho | * |
dc.author.google | Choi, Min Chul | * |
dc.author.google | Kim, Ki Hyung | * |
dc.author.google | Kim, Yong-Man | * |
dc.author.google | Lee, Yong Jae | * |
dc.author.google | Kang, Sokbom | * |
dc.author.google | Pujade-Lauraine, Eric | * |
dc.author.google | Shin, So-Jin | * |
dc.author.google | Hong, Dae Gy | * |
dc.author.google | Shim, Seung-Hyuk | * |
dc.author.google | Kim, Yun Hwan | * |
dc.author.google | Song, Taejong | * |
dc.author.google | Bae, Jaeman | * |
dc.author.google | Lee, Jong-Min | * |
dc.author.google | Lee, San Hui | * |
dc.author.google | Lee, Eun-Ju | * |
dc.author.google | Park, Sang-Il | * |
dc.author.google | Lee, Sung-Jong | * |
dc.author.google | Lee, Chulmin | * |
dc.author.google | Lee, Taek Sang | * |
dc.author.google | Chang, Suk-Joon | * |
dc.author.google | Kim, Min Kyu|KGOG Investigators | * |
dc.contributor.scopusid | 김윤환(55763947200) | * |
dc.date.modifydate | 20240220115825 | * |